Larvol Delta - ACELYRIN-INC-Announces-Longterm-32Week-Data-from-the-Phase-2b-Trial-of-Izokibep-in-Hidradenitis-Suppurativa-Demonstrating-Sustained-Responses-and-Deepening-Clinical-Benet--Improving-Quality-of-Life-for-Patients

izokibep (ABY-035) - ACELYRIN

https://www.globenewswire.com/news-release/2024/03/11/2843719/0/en/ACELYRIN-INC-Announces-Long-term-32-Week-Data-from-the-Phase-2b-Trial-of-Izokibep-in-Hidradenitis-Suppurativa-Demonstrating-Sustained-Responses-and-Deepening-Clinical-Benefit-Impro.html

Mar 11, 2024

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next